Company news
uniQure N.V. news in 2023
uniQure N.V.'s news releases, calls and decks from 2023, newest first.
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
December 18, 2023
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 7, 2023
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
November 28, 2023
uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
November 6, 2023
CSL and uniQure Win 2023 Prix Galien USA Award
October 26, 2023
uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
October 23, 2023
uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs
October 4, 2023
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy
September 4, 2023
uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
July 31, 2023
uniQure Announces Leadership Addition to Support Advancement of Clinical Programs
June 25, 2023
uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
June 20, 2023
uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy
June 19, 2023
CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B
June 19, 2023
uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million
May 14, 2023
uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 8, 2023
uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 1, 2023
uniQure to Participate in Multiple Upcoming Industry Conferences in March
March 1, 2023
uniQure Announces 2022 Financial Results and Highlights Recent Company Progress
February 26, 2023
uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
February 22, 2023
uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B
February 20, 2023
uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1
January 30, 2023